Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry.

Published

Journal Article

BACKGROUND: The management strategies for Barrett's esophagus (BE) that contains high-grade dysplasia (HGD) include intensive endoscopic surveillance, photodynamic therapy, thermal ablation, EMR, and esophagectomy. OBJECTIVE: To assess the safety and effectiveness of endoscopic circumferential balloon-based ablation by using radiofrequency energy for treating BE HGD. DESIGN: Multicenter U.S. registry. SETTING: Sixteen academic and community centers; treatment period from September 2004 to March 2007. PATIENTS: Patients with histologic evidence of intestinal metaplasia (IM) that contained HGD confirmed by at least 2 expert pathologists. A prior EMR was permitted, provided that residual HGD remained in the BE region for ablation. INTERVENTION: Endoscopic circumferential ablation with follow-up esophageal biopsies to assess the histologic response to treatment. OUTCOMES: Histologic complete response (CR) end points: (1) all biopsy specimen fragments obtained at the last biopsy session were negative for HGD (CR-HGD), (2) all biopsy specimens were negative for any dysplasia (CR-D), and (3) all biopsy specimens were negative for IM (CR-IM). RESULTS: A total of 142 patients (median age 66 years, interquartile range [IQR] 59-75 years) who had BE HGD (median length 6 cm, IQR 3-8 cm) underwent circumferential ablation (median 1 session, IQR 1-2). No serious adverse events were reported. There was 1 asymptomatic stricture and no buried glands. Ninety-two patients had at least 1 follow-up biopsy session (median follow-up 12 months, IQR 8-15 months). A CR-HGD was achieved in 90.2% of patients, CR-D in 80.4%, and CR-IM in 54.3%. LIMITATIONS: A nonrandomized study design, without a control arm, a lack of centralized pathology review, ablation and biopsy technique not standardized, and a relatively short-term follow-up. CONCLUSIONS: Endoscopic circumferential ablation is a promising modality for the treatment of BE that contains HGD. In this multicenter registry, the intervention safely achieved a CR for HGD in 90.2% of patients at a median of 12 months of follow-up.

Full Text

Duke Authors

Cited Authors

  • Ganz, RA; Overholt, BF; Sharma, VK; Fleischer, DE; Shaheen, NJ; Lightdale, CJ; Freeman, SR; Pruitt, RE; Urayama, SM; Gress, F; Pavey, DA; Branch, MS; Savides, TJ; Chang, KJ; Muthusamy, VR; Bohorfoush, AG; Pace, SC; DeMeester, SR; Eysselein, VE; Panjehpour, M; Triadafilopoulos, G; U.S. Multicenter Registry,

Published Date

  • July 2008

Published In

Volume / Issue

  • 68 / 1

Start / End Page

  • 35 - 40

PubMed ID

  • 18355819

Pubmed Central ID

  • 18355819

Electronic International Standard Serial Number (EISSN)

  • 1097-6779

Digital Object Identifier (DOI)

  • 10.1016/j.gie.2007.12.015

Language

  • eng

Conference Location

  • United States